Gilead Under Gun to Mass-Produce Virus Drug or Risk Exclusivity

Bookmark
(Bloomberg Law) -- Gilead Sciences Inc. has patent exclusivity on its potential Covid-19 treatment remdesivir for the next 15 years—poising the company for major profits if the drug is successful i...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.